Methylation, gene expression and the chromatin connection in cancer (Review)

International Journal of Molecular Medicine

Volumn 4, Issue 4, 1999, Pages 333-350

  Gray, Steven G ^a   Eriksson, Therese ^a   Ekström, Tomas J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chromatin; Gene expression; Methylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CELL NUCLEUS RECEPTOR; DNA; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HORMONE RECEPTOR; METHYL CPG BINDING PROTEIN 2; METHYL GROUP; RETINOBLASTOMA PROTEIN; THYMINE;

ARTICLE; CANCER GENETICS; CHROMATIN STRUCTURE; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 7P; CPG ISLAND; DNA METHYLATION; GENE CONVERSION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; ANIMAL; CHROMATIN; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; REVIEW;

ANIMALS; CHROMATIN; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0033209757     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.4.4.333     Document Type: Article

References (344)

1. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA and Gehrke C: Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 10: 2709-2721, 1982.
2. Tykocinski ML and Max EE: CG dinucleotide clusters in MHC genes and in 5' demethylated genes. Nucleic Acids Res 12: 4385-4396, 1984.
3. Schmutte C and Jones PA: Involvement of DNA methylation in human carcinogenesis. Biol Chem 379: 377-388, 1998.
4. Jones PA and Gonzalgo ML: Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sei USA 94: 2103-2105, 1997.
5. Feil R, Charlton J, Bird AP, Walter J and Reik W: Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. Nucleic Acids Res 22: 695-696, 1994.
6. Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T and Nagao M: Establishment of methylationsensitive- representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sei USA 94: 2284-2289, 1997.
7. Li E, Bestor TH and Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926, 1992.
8. Okano M, Xie SP and Li E: Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19: 219-220, 1998.
9. Gaudet F, Talbot D, Leonhardt H and Jaenisch R: A short DNA methyltransferase isoform restores methylation in vivo. J Biol Chem 273: 32725-32729, 1998.
10. Juttermann R, Li E and Jaenisch R: Toxicity of 5-aza-2'- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sei USA 91: 11797-11801, 1994.
11. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M and Clark SJ: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 57: 2229-2237, 1997.
12. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sei USA 91: 9700-9704, 1994.
13. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/ pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
14. Liggett WH Jr and Sidransky D: Role of the pi6 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
15. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F and Shaw P: Germ-line mutations of the pl6INK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 25: 1376-1381, 1997.
16. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, Leung WT, Wu S and Lee JC: High frequency of pl6INK4A gene alterations in hepatocellular carcinoma. Oncogene 18: 789-795, 1999.
17. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM and Johnson PJ: Detection of aberrant pi6 methylation in the plasma and serum of liver cancer patients. Cancer Res 59: 71-73, 1999.
18. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J and Hirohashi S: Inactivation of pl6INK4 in hepatocellular carcinoma. Hepatology 24: 575-579, 1996.
19. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K and Asakura H: pl6(Ink4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116: 394-400, 1999.
20. Herman JG, Jen J, Merlo A and Baylin SB: Hypermethylationassociated inactivation indicates a tumor suppressor role for pl5INK4B. Cancer Res 56: 722-727, 1996.
21. Rideout WM III, Eversole-Cire P, Spruck CH III, Hustad CM, Coetzee GA, Gonzales FA and Jones PA: Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol 14: 6143-6152, 1994.
22. Fijii K, Biel MA, Zhou W, Weitzman SA, Baylin SB and Gabrielson E: Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 16: 2159-2164, 1998.
23. Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H and Hirohashi S: DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 29: 703-709, 1999.
24. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M and Hirohashi S: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 71:355-359, 1997.
25. Mancini DN, Rodenhiser DI, Ainsworth PJ, Omalley FP, Singh SM, Xing WR and Archer TK: Cpg methylation within the 5' regulatory region of the Brcal gene is tumor specific and includes a putative Creb binding site. Oncogene 16: 1161-1169, 1998.
26. Choi EK, Uyeno S, Nishida N, Okumoto T, Fujimura S, Aoki Y, Nata M, Sagisaka K, Fukuda Y, Nakao K, Yoshimoto T, Kim YS and Ono T: Alterations of c-fos gene methylation in the processes of aging and tumorigenesis in human liver. Mutat Res 354: 123-128, 1996.
27. Nambu S, Inoue K and Saski H: Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn J Cancer Res 78: 695-704, 1987.
28. Ogata N, Kamimura T and Asakura H: Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 13: 31-37, 1991.
29. Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS and Hsu HC: Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 17: 35-41, 1993.
30. Liu YW, Chang KJ and Liu YC: DNA hypomethylation of proliferating cell nuclear antigen gene in human hepatocellular carcinoma is not due to cell proliferation. Cancer Lett 70: 189-196, 1993.
31. Li XR, Kogner P, Sandstedt B, Haas OA and Ekström TJ: Promoter-specific methylation and expression alterations of Igf2 and H19 are involved in human hepatoblastoma. Int J Cancer 75: 176-180, 1998.
32. Archey WB, Sweet MP, Alig GC and Arrick B A: Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta 3. Cancer Res 59: 2292-2296, 1999.
33. Deng G, Chen A, Hong J, Chae HS and Kim YS: Methylation of CpG in a small region of the hMLHl promoter invariably correlates with the absence of gene expression. Cancer Res 59: 2029-2033, 1999.
34. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG and Meltzer S J: Hypermethylation of the hMLHl gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59: 1090-1095, 1999.
35. Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene 06-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
36. Cheng NC, Beitsma M, Chan A, Op den Camp I, Westerveld A, Pronk J and Versteeg R: Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. Oncogene 13: 1737-1744, 1996.
37. Cheng NC, Chan AJ, Beitsma MM, Speleman F, Westerveld A and Versteeg R: A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands lp35-36. 1. Hum Mol Genet 5: 309-317, 1996.
38. Sun L, Hui AM, Kanai Y, Sakamoto M and Hirohashi S: Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 88:1165-1170, 1997.
39. Melki JR, Warnecke P, Vincent PC and Clark SJ: Increased DNA methyltransferase expression in leukaemia. Leukemia 12: 311-316, 1998.
40. El-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR and Baylin SB: High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sei USA 88: 3470-3474, 1991.
41. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV and Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 59: 2302-2306, 1999.
42. Lengauer C, Kinzler KW and Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sei USA 94: 2545-2550, 1997.
43. Canova C, Chevalier G, Remy S, Brächet P and Wion D: Epigenetic control of programmed cell death - inhibition by 5-azacytidine of 1, 25-dihydroxyvitamin D3-induced programmed cell death in C6. 9 glioma cells. Mech Ageing Dev 101: 153-166, 1998.
44. Zardo G, Marenzi S and Caiafa P: Hl histone as a trans-acting factor involved in protecting genomic DNA from full methylation. Biol Chem 379: 647-654, 1998.
45. Jost JP: Nuclear extracts of chicken embryos promote an active demethylation of DNA by excision repair of 5-methyldeoxycytidine. Proc Natl Acad Sei USA 90: 4684-4688, 1993.
46. Weiss A, Keshet I, Razin A and Cedar H: DNA demethylation in vitro: involvement of RNA. Cell 86: 709-718, 1996.
47. Leighton PA, Saam JR, Ingram RS, Stewart CL and Tilghman SM: An enhancer deletion affects both H19 and IGF2 expression. Genes Dev 9: 2079-2089, 1995.
48. Ekström TJ, Cui H, Li X and Ohlsson R: Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 121: 309-316, 1995.
49. Zhan S, Shapiro DN and Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94: 445-448, 1994.
50. Feinberg AP, Rainier S and De Baun MR: Genomic imprinting, DNA methylation, and cancer. J Natl Cancer Inst Monogr 21-26, 1995.
51. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ and Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362:749-751, 1993.
52. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL and Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 7: 433-439, 1994.
53. (published erratum appears in Nat Genet 8: 203, 1994)
54. Yballe CM, Vu TH and Hoffman AR: Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 81: 1607-1612, 1996.
55. McCann AH, Miller N, A OM, Pedersen I, Keogh K, Gorey T and Dervan PA: Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 5: 1123-1127, 1996.
56. Uyeno S, Aoki Y, Nata M, Sagisaka K, Kayama T, Yoshimoto T and Ono T: IGF2 but not H19 shows loss of imprinting in human glioma. Cancer Res 56: 5356-5359, 1996.
57. Albrecht S, Waha A, Koch A, Kraus JA, Goodyer CG and Pietsch T: Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma. J Neuropathol Exp Neurol 55: 1270-1276, 1996.
58. Douc-Rasy S, Barrois M, Fogel S, Ahomadegbe JC, Stehelin D, Coll J and Riou G: High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 12: 423-430, 1996.
59. Vu TH, Yballe C, Boonyanit S and Hoffman AR: Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab 80: 1670-1676, 1995.
60. Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M and Toyota T: Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett 107: 105-108, 1996.
61. Zhan S, Shapiro DN and Helman LJ: Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 11: 2503-2507, 1995.
62. Van Gurp RJ, Oosterhuis JW, Kalscheuer V, Mariman EC and Looijenga LH: Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 86: 1070-1075, 1994.
63. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R and Ekström TJ: Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 11: 221-229, 1995.
64. Li X, Nong Z, Ekström C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekström TJ and Schirmacher P: Disrupted IGF2 promoter control by silencing of promoter PI in human hepatocellular carcinoma. Cancer Res 57: 2048-2054, 1997.
65. Hashimoto K, Azuma C, Koyama M, Ohashi K, Kamiura S, Nobunaga T, Kimura T, Tokugawa Y, Kanai T and Saji F: Loss of imprinting in choriocarcinoma. Nat Genet 9: 109-110, 1995.
66. Mishina M, Ogawa O, Kinoshita H, Oka H, Okumura K, Mitsumori K, Kakehi Y, Reeve AE and Yoshida O: Equivalent parental distribution of frequently lost alleles and biallelic expression of the H19 gene in human testicular germ cell tumors. Jpn J Cancer Res 87: 816-823, 1996.
67. Verkerk AJ, Ariel I, Dekker MC, Schneider T, van Gurp RJ, De Groot N, Gillis AJ, Oosterhuis JW, Hochberg AA and Looijenga LH: Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 14: 95-107, 1997.
68. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T and Takahashi T: Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 10: 1193-1198, 1995.
69. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993.
70. Rainier S, Dobry CJ and Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Res 55: 1836-1838, 1995.
71. Lindahl T: Instability and decay of the primary structure of DNA. Nature 362: 709-715, 1993.
72. Shen JC, Rideout WM III and Jones PA: The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res 22: 972-976, 1994.
73. Schmutte C, Yang AS, Beart RW and Jones PA: Base excision repair of U:G mismatches at a mutational hotspot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors. Cancer Res 55: 3742-3746, 1995.
74. Wainfan E and Poirier LA: Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 52:2071s-2077s, 1992.
75. Shen JC, Rideout WMd and Jones PA: High frequency mutagenesis by a DNA methyltransferase. Cell 71: 1073-1080, 1992.
76. Laird PW and Jaenisch R: DNA methylation and cancer. Hum Mol Genet 3: 1487-1495, 1994.
77. Cai J, Mao Z, Hwang JJ and Lu SC: Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 58: 1444-1450, 1998.
78. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
79. Mancini D, Singh S, Ainsworth P and Rodenhiser D: Constitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RBI). Am J Hum Genet 61: 80-87, 1997.
80. Richards CA and Huber BE: Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum Gene Ther 4: 143-150, 1993.
81. Laker C, Meyer J, Schopen A, Friel J, Heberlein C, Ostertag W and Stocking C: Host c/s-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 72: 339-348, 1998.
82. De Pinho RA: Transcriptional repression. The cancer-chromatin. Nature 391: 533, 535-536, 1998.
83. Hassig CA and Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300-308, 1997.
84. Allfrey V, Faulkner RM and Mirsky AE: Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sei USA 51: 786-794, 1964.
85. Turner BM and O'Neill LP: Histone acetylation in chromatin and chromosomes. Semin Cell Biol 6: 229-236, 1995.
86. Taunton J, Hassig CA and Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408-411, 1996.
87. Brownell JE and Allis CD: Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 6: 176-184, 1996.
88. Mizzen CA and Allis CD: Linking histone acetylation to transcriptional regulation. Cell Mol Life Sei 54: 6-20, 1998.
89. Ogryzko VV, Schütz RL, Russanova V, Howard BH and Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959, 1996.
90. Bannister AJ and Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 384: 641-643, 1996.
91. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH and Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein El A. Nature 382: 319-324, 1996.
92. Candau R, Moore PA, Wang L, Barlev N, Ying CY, Rosen CA and Berger SL: Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5. Mol Cell Biol 16: 593-602, 1996.
93. Inoue M, Isomura M, Ikegawa S, Fujiwara T, Shin S, Moriya H and Nakamura Y: Isolation and characterization of a human cDNA clone (GCN5L1) homologous to GCN5, a yeast transcription activator. Cytogenet Cell Genet 73: 134-136, 1996.
94. Smith ER, Belote JM, Schütz RL, Yang XJ, Moore PA, Berger SL, Nakatani Y and Allis CD: Cloning of Drosophila GCN5: conserved features among metazoan GCN5 family members. Nucleic Acids Res 26: 2948-2954, 1998.
95. Wang L, Mizzen C, Ying C, Candau R, Barlev N, Brownell J, Allis CD and Berger SL: Histone acetyltransferase activity is conserved between yeast and human GCN5 and is required for complementation of growth and transcriptional activation. Mol Cell Biol 17:519-527, 1997.
96. Chen H, Lin RJ, Schütz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y and Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90: 569-580, 1997.
97. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ and BW OM: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198, 1997.
98. Siddique H, Zou JP, Rao VN and Reddy ES: The BRCA2 is a histone acetyltransferase. Oncogene 16: 2283-2285, 1998.
99. Yamamoto T and Horikoshi M: Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60. J Biol Chem 272: 30595-30598, 1997.
100. Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T, Workman J, Wang L, Berger SL, Kouzarides T, Nakatani Y and Allis CD: The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87: 1261-1270, 1996.
101. Kundu TK, Wang ZX and Roeder RG: Human TFIIIC relieves chromatin-mediated repression of RNA polymerase III transcription and contains an intrinsic histone acetyltransferase activity. Mol Cell Biol 19: 1605-1615, 1999.
102. Neuwald AF and Landsman D: GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem Sei 22: 154-155, 1997.
103. Dutnall RN, Tafrov ST, Sternglanz R and Ramakrishnan V: Structure of the histone acetyltransferase Hatl: a paradigm for the GCN5-related N-acetyltransferase superfamily. Cell 94: 427-438, 1998.
104. Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y and Burley SK: Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase. Cell 94: 439-449, 1998.
105. Clements A, Rojas JR, Trievel RC, Wang L, Berger SL and Marmorstein R: Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A. EMBO J 18: 3521-3532, 1999.
106. Lin Y, Fletcher CM, Zhou J, Allis CD and Wagner G: Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A. Nature 400: 86-89, 1999.
107. Janknecht R and Hunter T: Versatile molecular glue. Transcriptional control. Curr Biol 6: 951-954, 1996.
108. Janknecht R and Hunter T: Transcription. A growing coactivator network. Nature 383: 22-23, 1996.
109. Giles RH, Peters DJ and Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 178-183, 1998.
110. Zhang W and Bieker JJ: Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sei USA 95: 9855-9860, 1998.
111. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP and Ge H: Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7: 689-692, 1997.
112. Munshi N, Merika M, Yie J, Senger K, Chen G and Thanos D: Acetylation of HMG I(Y) by CBP turns off IFNbeta expression by disrupting the enhanceosome. Mol Cell 2: 457-467, 1998.
113. Herrera JE, Sakaguchi K, Bergel M, Trieschmann L, Nakatani Y and Bustin M: Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes. Mol Cell Biol 19: 3466-3473, 1999.
114. Hung HL, Lau J, Kim AY, Weiss MJ and Blobel GA: CREBbinding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol 19: 3496-3505, 1999.
115. Kuo M-H and Allis C: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20: 615-626, 1998.
116. Furukawa Y, Kawakami T, Sudo K, Inazawa J, Matsumine A, Akiyama T and Nakamura Y: Isolation and mapping of a human gene (RPD3L1) that is homologous to RPD3, a transcription factor in Saccharomyces ce revis iae. Cytogenet Cell Genet 73: 130-133, 1996.
117. Yang WM, Inouye C, Zeng Y, Bearss D and Seto E: Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sei USA 93: 12845-12850, 1996.
118. Dangond F, Hafler DA, Tong JK, Randall J, Kojima R, Utku N and Gullans SR: Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biophys Res Commun 242: 648-652, 1998.
119. Emiliani S, Fischle W, van Lint C, Al-Abed Y and Verdin E: Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sei USA 95: 2795-2800, 1998.
120. Yang WM, Yao YL, Sun JM, Davie JR and Seto E: Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 272: 28001-28007, 1997.
121. Grozinger CM, Hassig CA and Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc Natl A, cad Sei USA 96: 4868-4873, 1999.
122. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W and Verdin E: A new family of human histone deacetylases related to Saccharomyces cerevisiae HDAlp. J Biol Chem 274: 11713-11720, 1999.
123. Verdel A and Khochbin S: Identification of a new family of higher eukaryotic histone deacetylases - coordinate expression of differentiation-dependent chromatin modifiers. J Biol Chem 274: 2440-2445, 1999.
124. Leipe DD and Landsman D: Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic Acids Res 25: 3693-3697, 1997.
125. Khochbin S and Wolffe AP: The origin and utility of histone deacetylases. FEBS Lett 419: 157-160, 1997.
126. Ribiero RCJ, Kushner PJ and Baxter JD: The nuclear hormone receptor gene superfamily. Annu Rev Med 46: 443-453, 1995.
127. Mangelsdorf DJ and Evans RM: The RXR heterodimers and orphan receptors. Cell 83: 841-850, 1995.
128. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
129. Kastner P, Mark M and Chambon P: Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83: 859-869, 1995.
130. Beato M, Herrlich P and Schutz G: Steroid hormone receptors: many actors in search of a plot. Cell 83: 851-857, 1995.
131. Perlmann T and Evans RM: Nuclear receptors in Sicily: all in the famiglia. Cell 90: 391-397, 1997.
132. Heinzel T, Lavinsky RM, Mullen TM, Söderström M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK and Rosenfeld MG: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43-48, 1997.
133. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N and De Pinho RA: Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387: 49-55, 1997.
134. Hassig CA, Fleischer TC, Billin AN, Schreiber SL and Ayer DE: Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89: 341-347, 1997.
135. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E and Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349-356, 1997.
136. Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P and Reinberg D: Histone deacetylases and SAP 18, a novel polypeptide, are components of a human Sin3 complex. Cell 89: 357-364, 1997.
137. Kadosh D and Struhl K: Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 89: 365-371, 1997.
138. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL and Evans RM: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89: 373-380, 1997.
139. Söderström M, Vo A, Heinzel T, Lavinsky RM, Yang WM, Seto E, Peterson DA, Rosenfeld MG and Glass CK: Differential effects of nuclear receptor corepressor (N-CoR) expression levels on retinoic acid receptor-mediated repression support the existence of dynamically regulated corepressor complexes. Mol Endocrinol 11:682-692, 1997.
140. Li H, Leo C, Schroen DJ and Chen JD: Characterization of receptor interaction and transcriptional repression by the co-repressor SMRT. Mol Endocrinol 11: 2025-2037, 1997.
141. Sommer A, Hilfenhaus S, Menkel A, Kremmer E, Seiser C, Loidl P and Luscher B: Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol 7: 357-365, 1997.
142. Pazin MJ and Kadonaga JT: What's up and down with histone deacetylation and transcription? Cell 89: 325-328, 1997.
143. Schreiber-Agus N and De Pinho RA: Repression by the Mad (Mxi)-Sin3 complex. Bioessays 20: 808-818, 1998.
144. Zhang Y, Sun ZW, Iratni R, Erdjument-Bromage H, Tempst P, Hampsey M and Reinberg D: SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell 1: 1021-1031, 1998.
145. Laherty CD, Billin AN, Lavinsky RM, Yochum GS, Bush AC, Sun JM, Mullen TM, Davie JR, Rose DW, Glass CK, Rosenfeld MG, Ayer DE and Eisenman RN: SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell 2: 33-42, 1998.
146. Xu L, Lavinsky RM, Dåsen JS, Flynn SE, Mclnerney EM, Mullen TM, Heinzel T, Szeto D, Korzus E, Kurokawa R, Aggarwal AK, Rose DW, Glass CK and Rosenfeld MG: Signal-specific co-activator domain requirements for Pit-1 activation. Nature 395: 301-306, 1998.
147. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG and Rose DW: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sei USA 95: 2920-2925, 1998.
148. Wong CW and Privalsky ML: Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol 18: 5500-5510, 1998.
149. Muscat GE, Burke LJ and Downes M: The corepressor N-CoR and its variants RIP 13a and RIP13Deltal directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res 26: 2899-2907, 1998.
150. Wong C-W and Privalsky ML: Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors. Mol Cell Biol 18: 5724-5733, 1998.
151. Kurokawa R, Kalafus D, Ogliastro MH, Kioussi C, Xu L, Torchia J, Rosenfeld MG and Glass CK: Differential use of CREB binding protein-coactivator complexes. Science 279: 700-703, 1998.
152. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, Mclnerney EM, Mullen TM, Glass CK and Rosenfeld MG: Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279: 703-707, 1998.
153. Grant PA, Duggan L, Cote J, Roberts SM, Brownell JE, Candau R, Ohba R, Owen-Hughes T, Allis CD, Winston F, Berger SL and Workman JL: Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 11:1640-1650, 1997.
154. Grant PA, Schieltz D, Pray-Grant MG, Steger DJ, Reese JC, Yates JR III and Workman JL: A subset of TAFiis are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation. Cell 94: 45-53, 1998.
155. Forsberg EC, Lam LT, Yang XJ, Nakatani Y and Bresnick EH: Human histone acetyltransferase GCN5 exists in a stable macromolecular complex lacking the adapter ADA2. Biochemistry 36: 15918-15924, 1997.
156. Ogryzko VV, Kotani T, Zhang X, Schlitz RL, Howard T, Yang XJ, Howard BH, Qin J and Nakatani Y: Histone-like TAFs within the PCAF histone acetylase complex. Cell 94: 35-44, 1998.
157. Martinez E, Kundu TK, Fu J and Roeder RG: A human SPT3- TAFII31-GCN5-L acetylase complex distinct from transcription factor IID. J Biol Chem 273: 23781-23785, 1998.
158. Struhl K and Moqtaderi Z: The TAFs in the HAT. Cell 94: 1-4, 1998.
159. Dallas PB, Cheney IW, Liao DW, Bowrin V, Byam W, Pacchione S, Kobayashi R, Yaciuk P and Moran E: p300/Creb binding protein-related protein p270 is a component of mammalian Swi/Snf complexes. Mol Cell Biol 18: 3596-3603, 1998.
160. Wade PA, Jones PL, Vermaak D and Wolffe AP: A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase. Curr Biol 8: 843-846, 1998.
161. Cho H, Orphanides G, Sun XQ, Yang XJ, Ogryzko V, Lees E, Nakatani Y and Reinberg D: A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol 18: 5355-5363, 1998.
162. Tong JK, Hassig CA, Schnitzler GR, Kingston RE and Schreiber SL: Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395: 917-921, 1998.
163. Xue YT, Wong JM, Moreno GT, Young MK, Cote J and Wang WD: NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2: 851-861, 1998.
164. Pollard KJ and Peterson CL: Chromatin remodelling: a marriage between two families? Bioessays 20: 771-780, 1998.
165. Workman JL and Kingston RE: Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67: 545-579, 1998.
166. Jeddeloh JA, Stokes TL and Richards EJ: Maintenance of genomic methylation requires a SW12/SNF2-like protein. Nat Genet 22: 94-97, 1999.
167. Brand M, Yamamoto K, Staub A and Tora L: Identification of TATA-binding protein-free TAFii-containing complex subunits suggests a role in nucleosome acetylation and signal transduction. J Biol Chem 274: 18285-18289, 1999.
168. Feng XH, Zhang Y, Wu RY and Derynck R: The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 12: 2153-2163, 1998.
169. Zhang Y, Feng XH and Derynck R: Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TFG-beta-induced transcription. Nature 396: 491, 1998.
170. Topper JN, Di Chiara MR, Brown JD, Williams AJ, Falb D, Collins T and Gimbrone MA: CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor beta transcriptional responses in endothelial cells. Proc Natl Acad Sei USA 95: 12735, 1998.
171. 170-Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP and Wang XF: TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol Biol Cell 9: 3309-3319, 1998.
172. Wong C, Rougier-Chapman EM, Frederick JP, Datto MB, Liberati NT, Li JM and Wang XF: Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol Cell Biol 19: 1821-1830, 1999.
173. Wotton D, Lo RS, Lee S and Massague J: A Smad transcriptional corepressor. Cell 97: 29-39, 1999.
174. Jin SK and Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384, 1998.
175. Currie RA: NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF. J Biol Chem 273: 1430-1434, 1998.
176. Li Q, Herrler M, Landsberger N, Kaludov N, Ogryzko VV, Nakatani Y and Wolffe AP: Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J 17: 6300-6315, 1998.
177. Li S, Moy L, Pittman N, Shue G, Aufiero B, Neufeld EJ, Le Leiko NS and Walsh MJ: Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein cut homolog, is associated with histone deacetylation. J Biol Chem 274: 7803-7815, 1999.
178. Hsieh JJD, Zhou SF, Chen L, Young DB and Hayward SD: CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sei USA 96: 23-28, 1999.
179. Criqui-Filipe P, Dueret C, Sauver-Michel M and Wasylyk B: Net, a negative Ras-switchable TCF, contains a second inhibition omain, the CID, that mediates repression through interactions with CtBP and de-acetylation. EMBO J 18: 3392-3403, 1999.
180. Cuisset L, Tichonicky L, Jaffray P and Delpech M: The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase. J Biol Chem 272: 24148-24153, 1997.
181. Cuisset L, Tichonicky L and Delpech M: A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate. Biochem Biophys Res Commun 246: 760-764, 1998.
182. Espinos E, Le van Thai A, Pomies C and Weber MJ: Cooperation between phosphorylation and acetylation processes in transcriptional control. Mol Cell Biol 19: 3474-3484, 1999.
183. Barlev NA, Poltoratsky V, Owen-Hughes T, Ying C, Liu L, Workman JL and Berger SL: Repression of GCN5 histone acetyltransferase activity via bromodomain-mediated binding and phosphorylation by the Ku-DNA-dependent protein kinase complex. Mol Cell Biol 18: 1349-1358, 1998.
184. Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi- Jaulin L, Girault JA, Robin P, Knibiehler M, Pritchard LL, Ducommun B, Trouche D and Harel-Bellan A: Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396: 184-186, 1998.
185. Albert AC, Denton M, Kermekchiev M and Pikaard CS: Histone acetyltransferase and protein kinase activities copurify with a putative Xenopus RNA polymerase I holoenzyme self-sufficient for promoter-dependent transcription. Mol Cell Biol 19: 796-806, 1999.
186. Tate PH and Bird AP: Effects of DNA methylation on DNAbinding proteins and gene expression. Curr Opin Genet Dev 3: 226-231, 1993.
187. Mostoslavsky R and Bergman Y: DNA methylation: regulation of gene expression and role in the immune system. Biochim Biophys Acta 1333: F29-F50, 1997.
188. Constancia M, Pickard B, Kelsey G and Reik W: Imprinting mechanisms. Genome Res 8: 881-900, 1998.
189. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F and Bird A: Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905-914, 1992.
190. Meehan RR, Lewis JD and Bird AP: Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 20: 5085-5092, 1992.
191. Nan X, Meehan RR and Bird A: Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21: 4886-4892, 1993.
192. Nan X, Tate P, Li E and Bird A: DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 16: 414-421, 1996.
193. Chandler SP, Guschin D, Landsberger N and Wolffe AP: The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA. Biochemistry 38: 7008-7018, 1999.
194. D'Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, M DU and Brown SD: Isolation, physical mapping, and Northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm Genome 7: 533-535, 1996.
195. Vilain A, Apiou F, Vogt N, Dutrillaux B and Malfoy B: -Assignment of the gene for methyl-CpG-binding protein 2 (MECP2) to human chromosome band Xq28 by in situ hybridization. Cytogenet Cell Genet 74: 293-294, 1996.
196. Adler DA, Quaderi NA, Brown SD, Chapman VM, Moore J, Tate P and Disteche CM: The X-linked methylated DNA binding protein, Mecp2, is subject to X inactivation in the mouse. Mamm Genome 6: 491-492, 1995.
197. Tate P, Skårnes W and Bird A: The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse. Nat Genet 12: 205-208, 1996.
198. Meehan RR, Lewis JD, McKay S, Kleiner EL and Bird AP: Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58: 499-507, 1989.
199. Cross SH, Meehan RR, Nan X and Bird A: A component of the transcriptional repressor MeCPl shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 16: 256-259, 1997.
200. Hendrich B and Bird AP: Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538-6547, 1998.
201. Emery P, Durand B, Mach B and Reith W: RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res 24: 803-807, 1996.
202. Huntriss J, Lorenzi R, Purewal A and Monk M: A methylationdependent DNA-binding activity recognising the methylated promoter region of the mouse Xist gene. Biochem Biophys Res Commun 235: 730-738, 1997.
203. Joel P, Shao W and Pratt K: A nuclear protein with enhanced binding to methylated Spl sites in the AIDS virus promoter. Nucleic Acids Res 21: 5786-5793, 1993.
204. Suetake I, Tajima S and Asano A: Identification of two novel mouse nuclear proteins that bind selectively to a methylated c-Myc recognizing sequence. Nucleic Acids Res 21: 2125-2130, 1993.
205. Buschhausen G, Wittig B, Graessmann M and Graessmann A: Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. Proc Natl Acad Sei USA 84: 1177-1181, 1987.
206. Kass SU, Landsberger N and Wolffe AP: DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol 7: 157-165, 1997.
207. Keshet I, Lieman-Hurwitz J and Cedar H: DNA methylation affects the formation of active chromatin. Cell 44: 535-543, 1986.
208. Wolffe AP: Packaging principle: how DNA methylation and histone acetylation control the transcriptional activity of chromatin. J Exp Zool 282: 239-244, 1998.
209. Kass SU, Pruss D and Wolffe AP: How does DNA methylation repress transcription? Trends Genet 13: 444-449, 1997.
210. Nan X, Campoy FJ and Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481, 1997.
211. Weitzel JM, Buhrmester H and Stratling WH: Chicken MARbinding protein ARBP is homologous to rat methyl-CpGbinding protein MeCP2. Mol Cell Biol 17: 5656-5666, 1997.
212. Hibino Y, Ohzeki H, Hirose N, Morita Y and Sugano N: Involvement of DNA methylation in binding of a highly repetitive DNA component to nuclear scaffold proteins from rat liver. Biochem Biophys Res Commun 252: 296-301, 1998.
213. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J and Wolffe AP: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191, 1998.
214. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN and Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389, 1998.
215. Bestor TH: Gene silencing. Methylation meets acetylation. Nature 393: 311-312, 1998.
216. Eden S, Hashimshony T, Keshet I and Cedar H: DNA methylation models histone acetylation. Nature 394: 842, 1998.
217. Razin A: CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 17: 4905-4908, 1998.
218. Ammerpohl O, Schmitz A, Steinmüller L and Renkawitz R: Repression of the mouse M-lysozyme gene involves both hindrance of enhancer factor binding to the methylated enhancer and histone deacetylation. Nucleic Acids Res 26: 5256-5260, 1998.
219. Pikaart MJ, Recillas-Targa F and Felsenfeld G: Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 12: 2852-2862, 1998.
220. Kudo S: Methyl-CpG-binding protein MeCP2 represses Splactivated transcription of the human leukosialin gene when the promoter is methylated. Mol Cell Biol 18: 5492-5499, 1998.
221. Coffee B, Zhang FP, Warren ST and Reines D: Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 22: 98-101, 1999.
222. De Rubertis F, Kadosh D, Henchoz S, Pauli D, Reuter G, Struhl K and Spierer P: The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast. Nature 384: 589-591, 1996.
223. Selker EU: Trichostatin A causes selective loss of DNA methylation in Neurospora. Proc Natl Acad Sei USA 95: 9430-9435, 1998.
224. Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A and Cedar H: Spl elements protect a CpG island from de novo methylation. Nature 371: 435-438, 1994.
225. Clark S J, Harrison J and Molloy PL: Spl binding is inhibited by (m)Cp(m)CpG methylation. Gene 195: 67-71, 1997.
226. Mummaneni P, Yates P, Simpson J, Rose J and Turker MS: The primary function of a redundant Spl binding site in the mouse aprt gene promoter is to block epigenetic gene inactivation. Nucleic Acids Res 26: 5163-5169, 1998.
227. Tulchinsky EM, Georgiev GP and Lukanidin EM: Novel AP-1 binding site created by DNA-methylation. Oncogene 12: 1737-1745, 1996.
228. Di Fiore B, Palena A, Felsani A, Palitti F, Caruso M and Lavia P: Cytosine methylation transforms an E2F site in the retinoblastoma gene promoter into a binding site for the general repressor methylcytosine-binding protein 2 (MeCP2). Nucleic Acids Res 27: 2852-2859, 1999.
229. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAFl. Science 277: 1996-2000, 1997.
230. Shibahara K and Stillman B: Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin. Cell 96: 575-585, 1999.
231. Herwig S and Strauss M: The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 246: 581-601, 1997.
232. Kasten MM and Giordano A: pRb and the Cdks in apoptosis and the cell cycle. Cell Death Differ 5: 132-140, 1998.
233. Taya Y: RB kinases and RB-binding proteins: new points of view. Trends Biochem Sei 22: 14-17, 1997.
234. Herrera RE, Chen F and Weinberg RA: Increased histone HI phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts. Proc Natl Acad Sei USA 93: 11510-11515, 1996.
235. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597-601, 1998.
236. De Luca P, Majello B and Lania L: Retinoblastoma protein tethered to promoter DNA represses TBP-mediated transcription. J Cell Biochem 70: 281-287, 1998.
237. Luo RX, Postigo AA and Dean DC: Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473, 1998.
238. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D and Harel- Bellan A: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601-605, 1998.
239. Mulligan G and Jacks T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 14: 223-229, 1998.
240. Ferriera R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A and Trouch D: The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sei USA 95: 10493-10498, 1998.
241. Stiegler P, De Luca A, Bagella L and Giordano A: The COOHterminal region of pRb2/pl30 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2Fdependent cyclin A promoter. Cancer Res 58: 5049-5052, 1998.
242. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998.
243. Trouche D, Cook A and Kouzarides T: The CBP co-activator stimulates E2F1/DP1 activity. Nucleic Acids Res 24: 4139-4145, 1996.
244. Trouche D and Kouzarides T: E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP. Proc Natl Acad Sei USA 93: 1439-1442, 1996.
245. Shao Z, Ruppert S and Robbins PD: The retinoblastomasusceptibility gene product binds directly to the human TATAbinding protein-associated factor TAFII250. Proc Natl Acad Sei USA 92: 3115-3119, 1995.
246. Garriga J, Limon A, Mayol X, Rane SG, Albrecht JH, Reddy EP, Andres V and Grana X: Differential regulation of the retinoblastoma family of proteins during cell proliferation and differentiation. Biochem J 333: 645-654, 1998.
247. Koken MH, Reid A, Quignon F, Chelbi-Alix MK, Davies JM, Kabarowski JH, Zhu J, Dong S, Chen S, Chen Z, Tan CC, Licht J, Waxman S, De The H and Zelent A: Leukemiaassociated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sei USA 94: 10255-10260, 1997.
248. Hodges M, Tissot C, Howe K, Grimwade D and Freemont PS: Nuclear structure '98: structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet 63: 297-304, 1998.
249. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818, 1998.
250. Guidez F, Wins S, Zhu J, Söderström M, Waxman S and Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91: 2634-2642, 1998.
251. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A and Pandolfi PP: Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126-135, 1998.
252. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr and Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814, 1998.
253. Hong Sil, David G, Wong CW, Dejean A and Privalsky ML: SMRT corepressor interacts with PLZF and with the PMIretinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sei USA 94: 9028-9033, 1997.
254. Collins SJ: Acute promyelocytic leukemia: relieving repression induces remission. Blood 91: 2631-2633, 1998.
255. Warrell RP, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
256. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG and Lazar MA: Aberrant recruitment of the nuclear receptor corepressor- histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191, 1998.
257. Lutterbach B, Westendorf JI, Linggi B, Patten A, Moniwa M, Davie JR, Huynh K, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E and Hiebert SW: ETO, a target of t(8;21) in acute leukemia interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18: 7176-7184, 1998.
258. Wang J, Hoshino T, Redner RL, Kajigaya S and Liu JM: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/ HDAC1 complex. Proc Natl Acad Sei USA 95: 10860-10865, 1998.
259. Wong C-W and Privalsky ML: Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha and BCL-6. J Biol Chem 273: 27695-27702, 1998.
260. Lossos IS, Bogomoski-Yahalome V, Yehuda O, Ben-Neriah S, Ben-Yehuda D, Leizerowitz R and Polliack A: A novel translocation (l;2)(p34;p21-22) in acute myelomonoblastic leukaemia. Cancer Genet Cytogenet 106: 78-79, 1998.
261. Wang J, Saunthararajah Y, Redner RL and Liu JM: Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML 1-ETO leukemia cells. Cancer Res 59: 2766-2769, 1999.
262. Nagao Y, French BA, Cai Y, French SW and Wan YJ: Inhibition of PPAR alpha/RXR alpha-mediated direct hyperplasia pathways during griseofulvin-induced hepatocarcinogenesis. J Cell Biochem 69: 189-200, 1998.
263. Chan JY, Chin W, Liew CT, Chang KS and Johnson PJ: Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer 34: 1015-1022, 1998.
264. 1ssa JPJ, Kantarjian H, Mohan A, S OB, Cortes J, Pierce S and Talpaz M: Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93: 2075-2080, 1999.
265. Zhang Y, Le Roy G, Seelig H-P, Lane WS and Reinberg D: The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95: 279-289, 1998.
266. Koipally J, Renold A, Kim J and Georgopoulos K: Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J 18: 3090-3100, 1999.
267. Avitahl N, Winandy S, Friedrich C, Jones B, Ge YM and Georgopoulos K: Ikaros sets thresholds for T cell activation and regulates chromosome propagation. Immunity 10: 333-343, 1999.
268. Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E, Winandy S, Viel A, Sawyer A, Ikeda T, Kingston R and Georgopoulos K: Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 10: 345-355, 1999.
269. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE and Housman DE: The translocation t(8;16)(pl l;pl3) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14: 33-41, 1996.
270. Aguiar RC, Chase A, Coulthard S, MacDonald DH, Carapeti M, Reiter A, Sohal J, Lennard A, Goldman JM and Cross NC: Abnormalities of chromosome band 8pll in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 90: 3130-3135, 1997.
271. Carapeti M, Aguiar RC, Goldman JM and Cross NC: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91: 3127-3133, 1998.
272. Liang J, Prouty L, Williams BJ, Dayton MA and Blanchard KL: Acute mixed lineage leukemia with an inv(8)(pl lq 13) resulting in fusion of the genes for MOZ and TIF2. Blood 92: 2118-2122, 1998.
273. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J and Zeleznik-Le N: All patients with the T(ll;16)(q23;pl3. 3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90: 535-541, 1997.
274. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A, Maseki N and Kaneko Y: Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(ll;16)(q23;pl3) chromosome translocation. Genes Chromosomes Cancer 20: 60-63, 1997.
275. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD and Zeleznik-Le NJ: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t( 11 ; 16) (q23;pl3. 3). Proc Natl Acad Sei USA 94: 8732-8737, 1997.
276. Taki T, Sako M, Tsuchida M and Hayashi Y: The t(ll;16) (q23;pl3) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89: 3945-3950, 1997.
277. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M and Hayashi Y: Adenoviral ElA-associated protein p300 is involved in acute myeloid leukemia with t(ll;22)(q23;ql3). Blood 90: 4699-4704, 1997.
278. Hillion J, Le Coniat M, Jonveaux P, Berger R and Bernard OA: AF6q21, a novel partner of the MLL gene in t(6;l I)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90: 3714-3719, 1997.
279. Bernard OA, Hillion J, Le Coniat M and Berger R: A new case of translocation t(6;ll)(q21;q23) in a therapy-related acute myeloid leukemia resulting in an MLL-AF6q21 fusion. Genes Chromosomes Cancer 22: 221-224, 1998.
280. Megonigal MD, Rappaport EF, Jones DH, Williams TM, Lovett BD, Kelly KM, Lerou PH, Moulton T, Budarf ML and Felix CA: t(ll;22)(q23;ql 1. 2) in acute myeloid leukemia of infant twins fuses Mil with hCdcrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc Natl Acad Sei USA 95: 6413-6418, 1998.
281. Kitabayashi I, Yokoyama A, Shimizu K and Ohki M: Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17: 2994-3004, 1998.
282. Doucas V, Tini M, Egan DA and Evans RM: Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sei USA 96: 2627-2632, 1999.
283. Fuks F, Milner J and Kouzarides T: BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17: 2531-2534, 1998.
284. Yarden RI and Brody LC: BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sei USA 96: 4983-4988, 1999.
285. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T: The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 18: 2449-2458, 1999.
286. Radkov SA, Touitou R, Brehm A, Rowe M, West M, Kouzarides T and Allday MJ: Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73: 5688-5697, 1999.
287. Nomura T, Khan MM, Kaul SC, Dong HD, Wadhwa R, Colmenares C, Kohno I and Ishii S: Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev 13:412-423, 1999.
288. Tokitou F, Nomura T, Khan MM, Kaul SC, Wadhwa R, Yasukawa T, Kohno I and Ishii S: Viral ski inhibits retinoblastoma protein (Rb)-mediated transcriptional repression in a dominant negative fashion. J Biol Chem 274: 4485-4488, 1999.
289. Randhawa GS, Bell DW, Testa JR and Feinberg AP: Identification and mapping of human histone acetylation modifier gene homologues. Genomics 51: 262-269, 1998.
290. Betz R, Gray SG, Ekström C, Larsson C and Ekström TJ: Human histone deacetylase 2, HDAC2 (human RPD3), is localized to 6q21 by radiation hybrid mapping. Genomics 52: 245-246, 1998.
291. Schindelhauer D, Hellebrand H, Grimm L, Bader I, Meitinger T, Wehnert M, Ross M and Meindl A: Long-range map of a 3. 5-Mb region in Xpl 1. 23-22 with a sequence-ready map from a 1. 1-Mb gene-rich interval. Genome Res 6: 1056-1069, 1996.
292. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 76: 897-902, 1998.
293. Archer SY, Meng S, Shei A and Hodin RA: p21(Wafl) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sei USA 95: 6791-6796, 1998.
294. Janson W, Brandner G and Siegel J: Butyrate modulates DNAdamage- induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 15: 1395-1406, 1997.
295. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H and Sakai T: Butyrate activates the WAF1/ Cipl gene promoter through Spl sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206, 1997.
296. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor activates the WAFl/Cipl gene promoter through the Spl sites. Biochem Biophys Res Commun 241: 142-150, 1997.
297. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K and Isobe K: Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIPl in p53- independent manner. Biochem Biophys Res Commun 237: 457-460, 1997.
298. Simon D, Munoz SJ, Maddrey WC and Knowles BB: Chromosomal rearrangements in a primary hepatocellular carcinoma. Cancer Genet Cytogenet 45: 255-260, 1990.
299. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, Ishikawa T, Nakagama H, Harada H, et al: Allelotype study of primary hepatocellular carcinoma. Cancer Res 51: 89-93, 1991.
300. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC and Chen DS: Frequent genetic alterations at the distal region of chromosome lp in human hepatocellular carcinomas. Cancer Res 54: 4188-4192, 1994.
301. Chen HL, Chen YC and Chen DS: Chromosome lp aberrations are frequent in human primary hepatocellular carcinoma. Cancer Genet Cytogenet 86: 102-106, 1996.
302. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, Bioulac-Sage P, Capron F, Schmitz A, Olschwang S and Thomas G: Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a highresolution allelotype. Cancer Res 57: 1986-1990, 1997.
303. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A and Dejean A: Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 18: 59-65, 1997.
304. Parada LA, Hallen M, Tranberg KG, Hagerstrand I, Bondeson L, Mitelman F and Johansson B: Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer. Genes Chromosomes Cancer 23: 26-35, 1998.
305. Werner M, Wilkens L, Nasarek A, Tchinda J and Komminoth P: Detection of karyotype changes in interphase cells: oligonucleotide- primed in situ labelling versus fluorescence in situ hybridization. Virchows Arch 430: 381-387, 1997.
306. Zimmermann U, Feneux D, Mathey G, Gayral F, Franco D and Bedossa P: Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features. Hepatology 26: 1492-1498, 1997.
307. Piao Z, Park C, Park JH and Kim H: Allelotype analysis of hepatocellular carcinoma. Int J Cancer 75: 29-33, 1998.
308. Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T and Nakamura Y: Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm lp occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 13: 163-167, 1995.
309. Kaghad M, Bonnet H, Yang A, Créancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D: Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
310. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M and Imaoka S: Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 111: 455-461, 1996.
311. Kaplanski C, Srivatanakul P and Wild CP: Frequent rearrangements at minisatellite loci D1S7 (lp33-35), D7S22 (7q36-ter) and D12S11 (12q24. 3-ter) in hepatitis B viruspositive hepatocellular carcinomas from Thai patients. Int J Cancer 72: 248-254, 1997.
312. Ding SF, Habib NA, Dooley J, Wood C, Bowles L and Delhanty JD: Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer 64: 1083-1087, 1991.
313. Ding SF, Delhanty JD, Dooley JS, Bowles L, Wood CB and Habib NA: The putative tumor suppressor gene on chromosome 5q for hepatocellular carcinoma is distinct from the MCC and APC genes. Cancer Detect Prev 17: 405-409, 1993.
314. Huang SF, Hsu HC and Fletcher JA: Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 111: 21-27, 1999.
315. Dennis PA and Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cationindependent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sei USA 88: 580-584, 1991.
316. De Souza AT, Hankins GR, Washington MK, Orton TC and Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11: 447-449, 1995.
317. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC and Jirtle RL: Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10: 1725-1729, 1995.
318. Piao Z, Choi Y, Park C, Lee WJ, Park JH and Kim H: Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett 120:39-43, 1997.
319. Yamada T, De Souza AT, Finkelstein S and Jirtle RL: Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sei USA 94: 10351-10355, 1997.
320. Bedossa P, Peltier E, Terris B, Franco D and Poynard T: Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21: 760-766, 1995.
321. Kiss A, Wang NJ, Xie JP and Thorgeirsson SS: Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-m
322. Zimonjic DB, Keck CL, Thorgeirsson SS and Popescu NC: Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 29: 1208-1214, 1999.
323. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K and Sasaki K: Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 29: 1858-1862, 1999.
324. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JWY and Johnson PJ: Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis - relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 154: 37-43, 1999.
325. Nakamura T, Iwamura Y, Kaneko M, Nakagawa K, Kawai K, Mitamura K, Futagawa T and Hayashi H: Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. Jpn J Clin Oncol 21: 325-329, 1991.
326. Walker GJ, Hayward NK, Falvey S and Cooksley WG: Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res 51: 4367-4370, 1991.
327. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu SX, Benedict WF and Sekiya T: Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 54: 4177-4182, 1994.
328. Murakami Y, Hayashi K, Hirohashi S and Sekiya T: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51: 5520-5525, 1991.
329. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et ah Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13. Science 265: 2088-2090, 1994.
330. Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T and Nakamura Y: Evidence for the presence of two tumoursuppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 72: 383-385, 1995.
331. Lin YW, Sheu JC, Huang GT, Lee HS, Chen CH, Wang JT, Lee PH and Lu FJ: Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. Eur J Cancer 35: 652-658, 1999.
332. Lee CW, Sorensen TS, Shikama N and La Thangue NB: Functional interplay between p53 and E2F through co-activator p300. Oncogene 16: 2695-2710, 1998.
333. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL and Halazonetis TD: CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 57: 3693-3696, 1997.
334. Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
335. Vassilev A, Yamauchi J, Kotani T, Prives C, Avantaggiati ML, Qin J and Nakatani Y: The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol Cell 2: 869-875, 1998.
336. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841, 1998.
337. Yuan ZM, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y and Kufe D: Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 274: 1883-1886, 1999.
338. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD and Berger SL: p53 sites acetylated in vitro by Pcaf and p300 are acetylated in vivo in response to Dna damage. Mol Cell Biol 19: 1202-1209, 1999.
339. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K: Recruitment of p300/CBP in p53- dependent signal pathways. Cell 89: 1175-1184, 1997.
340. Lill NL, Grossman SR, Ginsberg D, De Caprio J and Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827, 1997.
341. Gu W, Shi XL and Roeder RG: Synergistic activation of transcription by CBP and p53. Nature 387: 819-823, 1997.
342. Kang YK, Kim CJ, Kim WH, Kim HO, Kang GH and Kim YI: p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 432: 27-32, 1998.
343. Stacey MW, Wang JX, Byrd RL, Liu JM and Kearns WG: Nuclear receptor co-repressor gene localizes to 17pl 1. 2, a frequently deleted band in malignant disorders. Genes Chromosomes Cancer 25: 191-193, 1999.
344. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.